Babio Launches Rapid Procalcitonin (PCT) Test Card for Sepsis and Bacterial Infection Detection

Babio Launches Rapid Procalcitonin (PCT) Test Card for Sepsis and Bacterial Infection Detection

Jinan, China — Babio Biotechnology Co., Ltd. (BABIO), a leading Chinese manufacturer of in vitro diagnostic (IVD) products, has announced the release of its Procalcitonin (PCT) Test Card (Colloidal Gold Method) — a rapid, reliable tool designed for the qualitative detection of PCT levels in human serum, plasma, or whole blood.

Procalcitonin is a key biomarker for bacterial infection and sepsis, enabling clinicians to distinguish between bacterial and viral infections and to monitor antibiotic therapy. The Babio PCT Test Card delivers accurate results in just 15–20 minutes, supporting early clinical intervention in intensive care units, emergency departments, and hospital laboratories.

This colloidal gold-based rapid test features an intuitive design for point-of-care use, requiring only three drops (≈100 µL) of sample. Its clear visual results and simple operation make it ideal for laboratories and healthcare providers across Europe, Africa, Southeast Asia, and the Americas, where fast infection differentiation is critical to patient outcomes.

As an ISO 13485-certified manufacturer, Babio Biotechnology is recognized globally for its high-quality diagnostic reagents, rapid test kits, and transport media solutions. With distribution networks in more than 60 countries, Babio continues to deliver reliable, affordable, and high-performance diagnostic solutions to the global healthcare market.

For more information or business cooperation, please visit: https://www.babiocorp.com

#ProcalcitoninTest #PCTRapidTest #BabioBiotechnology #SepsisDiagnosis #IVDChina #InfectionDetection #PointOfCareTesting #ColloidalGoldAssay #ClinicalDiagnostics